Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysis
Background: : Mucinous adenocarcinoma is a rare subtype of lung cancer characterized by abnormal mucin production. We sought to investigate the clinical and pathological features of pulmonary mucinous adenocarcinomas and to identify prognostic factors. Methods: : This was a single-institution retros...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294222000600 |
| _version_ | 1818495194308280320 |
|---|---|
| author | Michelle Bradbury Deborah Akurang Abdullah Nasser Sara Moore Harmanjatinder S Sekhon Paul Wheatley-Price |
| author_facet | Michelle Bradbury Deborah Akurang Abdullah Nasser Sara Moore Harmanjatinder S Sekhon Paul Wheatley-Price |
| author_sort | Michelle Bradbury |
| collection | DOAJ |
| description | Background: : Mucinous adenocarcinoma is a rare subtype of lung cancer characterized by abnormal mucin production. We sought to investigate the clinical and pathological features of pulmonary mucinous adenocarcinomas and to identify prognostic factors. Methods: : This was a single-institution retrospective review of patients with pulmonary mucinous adenocarcinoma diagnosed between January 1, 2015 and December 31, 2020. Descriptive analysis included demographics, diagnostic data, and treatment modalities. The primary outcome was overall survival (OS). Results: : Fifty-six patients were included in the study. Median age was 65 years (range: 26-84), 30 (54%) were female, 48 (86%) had a smoking history, and 41 (73%) patients had ECOG performance status 0-1. Nearly half (26, 46%) were stage IV at presentation, while 11 (20%) presented as stage I, 10 (18%) stage II, and 9 (16%) stage III. Biomarker testing increased through the study period. Where performed, 4/48 (8%) cases were ALK positive, but there were no EGFR cases identified (0/36). Only 3/20 cases had PD-L1 expression >50%. Curative intent therapy was performed in 23 patients (17 had surgery +/- chemotherapy/radiation, 4 had radiotherapy alone, 2 had chemoradiation). Median OS in the entire population was 16.1 months (m). OS by stage was 50.0m for stage I, not reached for stage II, 20.7m for stage III, and 8.1m for stage IV. Conclusions: : The overall prognosis of pulmonary mucinous adenocarcinoma appears similar to that of non-mucinous adenocarcinomas, with distinct differences noted in the incidence of oncogenic driver mutations, particularly an absence of EGFR mutations. |
| first_indexed | 2024-12-10T18:17:15Z |
| format | Article |
| id | doaj.art-40e7cf055d524986a8d2bf3dd5dca26d |
| institution | Directory Open Access Journal |
| issn | 2468-2942 |
| language | English |
| last_indexed | 2024-12-10T18:17:15Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj.art-40e7cf055d524986a8d2bf3dd5dca26d2022-12-22T01:38:18ZengElsevierCancer Treatment and Research Communications2468-29422022-01-0132100570Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysisMichelle Bradbury0Deborah Akurang1Abdullah Nasser2Sara Moore3Harmanjatinder S Sekhon4Paul Wheatley-Price5Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, CanadaUniversity of Ottawa, Ottawa, CanadaDepartment of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, CanadaDepartment of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, CanadaDepartment of Pathology and Laboratory Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, CanadaDepartment of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, Ottawa, Canada; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada; Corresponding Author: Paul Wheatley-Price BSc, MBChB, FRCP (UK), MD, The Ottawa Hospital Cancer Centre, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Tel: (613) 737-7700 ext 70175, Fax: (613) 247-3511Background: : Mucinous adenocarcinoma is a rare subtype of lung cancer characterized by abnormal mucin production. We sought to investigate the clinical and pathological features of pulmonary mucinous adenocarcinomas and to identify prognostic factors. Methods: : This was a single-institution retrospective review of patients with pulmonary mucinous adenocarcinoma diagnosed between January 1, 2015 and December 31, 2020. Descriptive analysis included demographics, diagnostic data, and treatment modalities. The primary outcome was overall survival (OS). Results: : Fifty-six patients were included in the study. Median age was 65 years (range: 26-84), 30 (54%) were female, 48 (86%) had a smoking history, and 41 (73%) patients had ECOG performance status 0-1. Nearly half (26, 46%) were stage IV at presentation, while 11 (20%) presented as stage I, 10 (18%) stage II, and 9 (16%) stage III. Biomarker testing increased through the study period. Where performed, 4/48 (8%) cases were ALK positive, but there were no EGFR cases identified (0/36). Only 3/20 cases had PD-L1 expression >50%. Curative intent therapy was performed in 23 patients (17 had surgery +/- chemotherapy/radiation, 4 had radiotherapy alone, 2 had chemoradiation). Median OS in the entire population was 16.1 months (m). OS by stage was 50.0m for stage I, not reached for stage II, 20.7m for stage III, and 8.1m for stage IV. Conclusions: : The overall prognosis of pulmonary mucinous adenocarcinoma appears similar to that of non-mucinous adenocarcinomas, with distinct differences noted in the incidence of oncogenic driver mutations, particularly an absence of EGFR mutations.http://www.sciencedirect.com/science/article/pii/S2468294222000600mucinbiomarkerKRASALKsurvival |
| spellingShingle | Michelle Bradbury Deborah Akurang Abdullah Nasser Sara Moore Harmanjatinder S Sekhon Paul Wheatley-Price Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysis Cancer Treatment and Research Communications mucin biomarker KRAS ALK survival |
| title | Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysis |
| title_full | Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysis |
| title_fullStr | Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysis |
| title_full_unstemmed | Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysis |
| title_short | Clinicopathological features of pulmonary mucinous adenocarcinoma: A descriptive analysis |
| title_sort | clinicopathological features of pulmonary mucinous adenocarcinoma a descriptive analysis |
| topic | mucin biomarker KRAS ALK survival |
| url | http://www.sciencedirect.com/science/article/pii/S2468294222000600 |
| work_keys_str_mv | AT michellebradbury clinicopathologicalfeaturesofpulmonarymucinousadenocarcinomaadescriptiveanalysis AT deborahakurang clinicopathologicalfeaturesofpulmonarymucinousadenocarcinomaadescriptiveanalysis AT abdullahnasser clinicopathologicalfeaturesofpulmonarymucinousadenocarcinomaadescriptiveanalysis AT saramoore clinicopathologicalfeaturesofpulmonarymucinousadenocarcinomaadescriptiveanalysis AT harmanjatinderssekhon clinicopathologicalfeaturesofpulmonarymucinousadenocarcinomaadescriptiveanalysis AT paulwheatleyprice clinicopathologicalfeaturesofpulmonarymucinousadenocarcinomaadescriptiveanalysis |